IKT vs SAVA vs ACAD vs AVXL vs ACIU

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -86. 9% for AC Immune S. A. (ACIU). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of -22. 6%, compared to -94. 3% for Inhibikase Therapeutics, Inc. (IKT). Over 10 years, the gap is even starker: SAVA returned -38. 0% versus IKT's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 10β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 74% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 10% for AC Immune S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -86. 9% for AC Immune S. A. (ACIU). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AVXL: 340.

0% to $11. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Inhibikase Therapeutics, Inc. (IKT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -44. 6%, IKT: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IKT is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; AVXL is a small-cap quality compounder stock; ACIU is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.